LB Pharmaceuticals reports Q3 2026 results, appoints new CFO and CMO, and raises $150 million
LB Pharmaceuticals announced its third‑quarter 2026 financials and a corporate update. The company named Dr. Susan G. Kozauer as chief medical officer and Joseph Miller as chief financial officer. It completed a private placement that generated $150 million in gross proceeds and reported cash and short‑term investments of $403.8 million as of September 30 2026. The firm said the cash balance should support operations through the second quarter of 2029 and that it remains on track for a topline readout from the Phase 3 NOVA‑2 trial of its lead asset LB‑102 in schizophrenia in the first half of 2027.
Why it matters
The additional $150 million bolsters the company’s balance sheet, extending its cash runway to beyond Q2 2029, which should fund ongoing clinical trials and potential expansion into new indications. The leadership changes may enhance execution of the LB‑102 development program and preparation for a future commercial launch.
Key facts
- 1The company completed a private placement of $150.0 million in July 2026. globenewswire.com
- 2Net proceeds from the placement were about $140.9 million after fees. globenewswire.com
- 3Cash, cash equivalents and short‑term investments totaled $403.8 million as of September 30 2026. globenewswire.com
- 4R&D expenses were $51.5 million for the three months ended September 30 2026. sec.gov
- 5Topline data from the Phase 3 NOVA‑2 trial of LB‑102 in schizophrenia are expected in the first half of 2027. globenewswire.com
- 6Susan G. Kozauer, M.D., was appointed chief medical officer and Joseph Miller was appointed chief financial officer. globenewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.